AGIO – Agios Pharmaceuticals, Inc is a biopharmaceutical company, engaged in the discovery and development of medicines for the treatment of cancer and genetic disorders.
AGIO – Agios Pharmaceuticals, Inc
|Fundamentals||Previously closed at||50.35|
|Analysts opinion||Agios Pharma announced positive results for its phase 1 Drug AG-348, used to treat anaemia. The stock was upgraded by Canaccord Genuity and J. P Morgan to “Buy”. Analyst confidence meter, a proprietary algorithm of Stockal gives 66% buy based on analyst ratings.|
|Sentiments||AGIO fell, after having gained 8% Pre-Market today. The sentiment index is 100% negative according to Stockal proprietary algorithm.|
|Social Media Pulse||The stock has 10% lower social media chatter than usual.|